The intrinsic genetic and epigenetic regulator factors as therapeutic targets, and the effect on fetal globin gene expression.
The effort to induce fetal globin or Hb F gene expression as an alternative therapy for blood transfusion has been ongoing for few decades, with promising results evident in patients with hemoglobinopathies. Although the clinical outcomes have been satisfactory and significant, there are still concerns about the safety of Hb F inducers in the long-term. There are potent inducers which lose their potency and safety over the course of therapy. Area covered: In this work, efforts have been made to review the latest findings on intrinsic genetic and epigenetic factors which are able to induce the gene expression of fetal globin in adult patients with beta (β)-thalassemia Major, Intermedia and sickle cell disease (SCD). Expert commentary: To meet a satisfying therapeutic outcome in patients with hemoglobinopathies, in addition to adopting a potent Hb F inducer, a continuous level of gamma (γ)-globin gene over the course of therapy in safety condition also needs to be considered. Therefore, to reach this aim, it is suggested that the experiment designers consider the safety and long-term characteristics of the inducers simultaneously, by examining their synergistic effects.